LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

Search

Pfizer

Open

BrancheGesundheitswesen

22.71 1.07

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

22.43

Max

22.76

Schlüsselkennzahlen

By Trading Economics

Einkommen

2.6B

3B

Verkäufe

-4B

14B

KGV

Branchendurchschnitt

16.732

56.602

EPS

0.92

Dividendenrendite

7.72

Gewinnspanne

21.633

Angestellte

81,000

EBITDA

2B

4.5B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+26.88% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

7.72%

2.45%

Nächstes Ergebnis

29. Juli 2025

Nächste Dividendenausschüttung

13. Juni 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-14B

131B

Vorheriger Eröffnungskurs

21.64

Vorheriger Schlusskurs

22.71

Nachrichtenstimmung

By Acuity

43%

57%

150 / 382 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Pfizer Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

1. Mai 2025, 18:41 UTC

Wichtige Markttreiber

Arvinas Shares Drop; Cancels Two Drug Trials With Pfizer Amid Capital Markets Challenges

29. Apr. 2025, 11:24 UTC

Ergebnisse

Pfizer 1Q Revenue Slides as Paxlovid Sales Fade

15. Mai 2025, 15:20 UTC

Top News

New Allegations About Timing of Pfizer Covid Vaccine Passed to House Panel -- WSJ

12. Mai 2025, 22:14 UTC

Top News

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12. Mai 2025, 18:45 UTC

Top News

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12. Mai 2025, 17:14 UTC

Top News

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

12. Mai 2025, 09:02 UTC

Heiße Aktien

Stocks to Watch: Amazon, Tesla, Apple, Maersk -- WSJ

7. Mai 2025, 17:01 UTC

Top News

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says -- Barrons.com

7. Mai 2025, 09:30 UTC

Top News

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

5. Mai 2025, 15:13 UTC

Market Talk
Ergebnisse

Narrower Guidelines for Covid-19 Booster Wouldn't Limit BioNTech's Customer Base Much -- Market Talk

1. Mai 2025, 14:07 UTC

Ergebnisse

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1. Mai 2025, 11:58 UTC

Ergebnisse

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1. Mai 2025, 11:06 UTC

Ergebnisse

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1. Mai 2025, 10:48 UTC

Ergebnisse

Eli Lilly Earnings Beat Expectations. The Stock Is Falling. -- Barrons.com

29. Apr. 2025, 19:47 UTC

Ergebnisse

Pfizer Shares Rise on CEO's Optimism on Threatened Drug Tariffs -- Barrons.com

29. Apr. 2025, 18:11 UTC

Ergebnisse

Pfizer Stock's 7% Yield Makes It Look Like a Junk Bond -- But Better -- Barrons.com

29. Apr. 2025, 15:22 UTC

Ergebnisse

Pfizer Earnings Beat Isn't Enough to Ease Stock Worries -- Barrons.com

29. Apr. 2025, 12:03 UTC

Akquisitionen, Fusionen, Übernahmen

Pfizer Files 8K - Costs of Exits Or Disposals >PFE

29. Apr. 2025, 11:46 UTC

Ergebnisse

Pfizer Stock Gains After Earnings Beat. Tariffs Aren't the Only Worry for Wall Street. -- Barrons.com

29. Apr. 2025, 11:42 UTC

Ergebnisse

Pfizer Stock Falls After Earnings Beat. Tariffs Aren't the Only Worry. -- Barrons.com

29. Apr. 2025, 11:12 UTC

Ergebnisse

Pfizer Earnings Beat. Tariffs Uncertainty Hinders Guidance. -- Barrons.com

29. Apr. 2025, 10:52 UTC

Ergebnisse

Pfizer: Currently Trending Towards Upper End of 2025 Adj EPS Guidance Range

29. Apr. 2025, 10:51 UTC

Ergebnisse

Pfizer: Believe We Can Be Agile in Navigating Uncertain and Volatile External Environment

29. Apr. 2025, 10:50 UTC

Ergebnisse

Pfizer: On Track For Total Net Cost Savings $5.7B Through 2027

29. Apr. 2025, 10:47 UTC

Ergebnisse

Pfizer: Expects to Continue to De-Lever in Prudent Manner

29. Apr. 2025, 10:47 UTC

Ergebnisse

Pfizer: Current Fincl Guidance Does Not Anticipate Any Share Repurchases in 2025

29. Apr. 2025, 10:46 UTC

Ergebnisse

Pfizer: "Unable to Predict" Tariff Impact "At This Time"

29. Apr. 2025, 10:45 UTC

Ergebnisse

Pfizer: Reaffirmed Views Don't Currently Include Impact From Tariffs

29. Apr. 2025, 10:45 UTC

Ergebnisse

Pfizer 1Q EPS 52c >PFE

29. Apr. 2025, 10:45 UTC

Ergebnisse

Pfizer 1Q Adj EPS 92c >PFE

Peer-Vergleich

Kursveränderung

Pfizer Prognose

Kursziel

By TipRanks

26.88% Vorteil

12-Monats-Prognose

Durchschnitt 27.94 USD  26.88%

Hoch 32 USD

Tief 24 USD

Basierend auf 18 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Pfizer – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

18 ratings

5

Buy

13

Halten

0

Sell

Technischer Score

By Trading Central

22.855 / 23.85Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

150 / 382 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.